LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Inhaled corticosteroids and COVID-19 outcomes in asthma: the Israeli experience

Photo from wikipedia

Inhaled corticosteroids (ICS), alone or in combination with bronchodilators, are widely used in asthma [1]. ICS have potential immunosuppressive effects that may promote viral replication, delayed viral clearance and increased… Click to show full abstract

Inhaled corticosteroids (ICS), alone or in combination with bronchodilators, are widely used in asthma [1]. ICS have potential immunosuppressive effects that may promote viral replication, delayed viral clearance and increased risks of secondary infections [2, 3]. Furthermore, ICS use in asthma is associated with an increased risk of upper respiratory tract infections [2, 3]. Therefore, in the face of the current coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, concerns have been raised whether the use of ICS in asthmatic patients increases the risk of SARS CoV-2 infection and affects COVID-19 severity and mortality. The use of ICS is safe and people living with #asthma should continue to take their prescribed medication as usual during the #COVID19 pandemic https://bit.ly/3rOYIL2

Keywords: asthma israeli; covid outcomes; corticosteroids covid; covid; outcomes asthma; inhaled corticosteroids

Journal Title: ERJ Open Research
Year Published: 2022

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.